Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid, Box 8056, St. Louis, MO 63110, USA.
Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y.
Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts to modify anti-CD30 antibodies to improve binding of effector cells and enhance activity appears more promising, as does the development of novel antibody-drug conjugates (ADCs). ADCs offer the potential to deliver potent therapies with minimal toxicity. One highly active ADC, brentuximab vedotin (SGN-35), combines an anti-CD30 monoclonal antibody and the antitubulin agent monomethyl auristatin E. Initial phase 1 studies of brentuximab vedotin showed a 52% overall response rate in relapsed HL, with minimal toxicity. This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL.
治疗难治性或复发性经典霍奇金淋巴瘤（HL）仍然具有挑战性，但靶向免疫疗法最近已成为这些患者的潜在治疗选择。尽管第一代单克隆抗 CD30 抗体的疗效令人失望，但目前正在努力修饰抗 CD30 抗体以改善效应细胞的结合并增强其活性，这似乎更有希望，新型抗体药物偶联物（ADC）的开发也是如此。ADC 有可能以最小的毒性提供有效的治疗方法。一种高度有效的 ADC， Brentuximab vedotin（SGN-35），结合了一种抗 CD30 单克隆抗体和抗微管蛋白药物单甲基奥瑞他汀 E。Brentuximab vedotin 的初步 1 期研究显示，复发性 HL 的总缓解率为 52%，毒性最小。本文重点介绍了用于复发性或难治性经典 HL 的抗 CD30 抗体和 ADC 的开发。
